drugset / Trial / NCT02574130

Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria

NCT02574130

Completed 60 enrolled Thammasat University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the cure rate from ventilator-associated pneumonia (VAP) caused by Gram negative bacteria when administering add on nebulized amikacin to intravenous antibiotics compared to intravenous antibiotics alone.

Timeline

Start
2015-07
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Amikacin Small molecule 400 mg Inhaled

Indications

No indication recorded.